Effects of Different Doses of Dexmedetomidine on Fentanyl-induced Cough
NCT ID: NCT03126422
Last Updated: 2017-07-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
240 participants
INTERVENTIONAL
2017-05-01
2017-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients undergoing elective surgeries under general anesthesia will be randomly allocated to 4 groups (n = 60, each group). Dexmedetomidine 0, 0.03, 0.06, and 0.09 μg/kg/min will be pump-administered in 10 mins to groups I, II, III, and IV, respectively, followed by the induction of general anesthesia with intravenous fentanyl 4 μg/kg. The incidences and severity of cough that occurred within 2 min after the injection of fentanyl will be recorded, and the incidences of cardiovascular adverse events that occurred between the administration of the dexmedetomidine infusion and 2 min after tracheal intubation will be recorded.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Dexmedetomidine for Emergence Cough
NCT03622502
Efficacy of Dexmedetomidine for Cough Suppression in Patients Undergoing Thyroid Surgery
NCT03312413
Antitussive Effect of Single-dose Dexmedetomidine With Low-dose Remifentanil Infusion
NCT02208505
Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients
NCT00345384
Effects of Dexmedetomidine on OI, RI and Inflammatory Factors in Patients Undergoing Palatopalatyngoplasty.
NCT03612440
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dexmedetomidine 0 μg/kg/min
Dexmedetomidine
Pretreatment of different doses of dexmedetomidine
Dexmedetomidine 0.03 μg/kg/min
Dexmedetomidine
Pretreatment of different doses of dexmedetomidine
Dexmedetomidine 0.06 μg/kg/min
Dexmedetomidine
Pretreatment of different doses of dexmedetomidine
Dexmedetomidine 0.09 μg/kg/min
Dexmedetomidine
Pretreatment of different doses of dexmedetomidine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
Pretreatment of different doses of dexmedetomidine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients younger than 18 years old and older than 65 years old.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yangzhou University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhuan Zhang
Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the Affiliated Hospital of Yangzhou University, Yangzhou University
Yangzhou, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Zhou W, Zhang D, Tian S, Yang Y, Xing Z, Ma R, Zhou T, Bao T, Sun J, Zhang Z. Optimal dose of pretreated-dexmedetomidine in fentanyl-induced cough suppression: a prospective randomized controlled trial. BMC Anesthesiol. 2019 Jun 1;19(1):89. doi: 10.1186/s12871-019-0765-z.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20170413
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.